3期SELENE研究:伊布替尼联合BR/R-CHOP方案治疗经治滤泡性淋巴瘤或边缘区淋巴瘤患者
3期SELENE研究评估伊布替尼联合化学免疫治疗(CIT;BR或R-CHOP)用于复发/难治性滤泡性淋巴瘤(FL)或边缘区淋巴瘤(MZL)患者。403例既往接受过≥1线CIT的成人患者按1:1随机接受口服伊布替尼560 mg或安慰剂每日一次,联合6周期BR/R-CHOP。中位随访84个月,伊布替尼+CIT组中位无进展生存期(PFS)40.5个月 vs 安慰剂+CIT组23.8个月(HR 0.806,95%CI 0.626-1.037,P=0.0922),差异无统计学意义。
要点
- 伊布替尼+CIT组中位PFS 40.5个月 vs 安慰剂+CIT组23.8个月,HR 0.806(95%CI 0.626-1.037,P=0.0922),未达统计学显著。
- 两组中位总生存期均未达到(HR 0.980,95%CI 0.686-1.400)。
- ≥3级治疗中出现的不良事件(TEAE)发生率伊布替尼+CIT组85.6% vs 安慰剂+CIT组75.4%;两组各13例患者发生导致死亡的TEAE。
核心结论
- 在复发/难治性FL或MZL患者中,与安慰剂+CIT相比,伊布替尼联合CIT未显著改善PFS。
- 伊布替尼联合CIT的安全性特征与伊布替尼和CIT已知的安全性特征一致。
研究设计与样本
- 3期SELENE研究为随机、双盲、安慰剂对照试验,注册号NCT01974440。
- 纳入既往接受过≥1线CIT的成人复发/难治性FL或MZL患者,按1:1随机分配至口服伊布替尼560 mg每日一次或安慰剂每日一次,联合6周期BR或R-CHOP。
- 共随机403例患者:伊布替尼+CIT组202例,安慰剂+CIT组201例;大多数患者接受BR(90.3%),大多数为FL(86.1%)。
- 主要终点为研究者评估的PFS。
主要发现
- 中位随访84个月,伊布替尼+CIT组中位PFS为40.5个月,安慰剂+CIT组为23.8个月(HR 0.806,95%CI 0.626-1.037,P=0.0922)。
- 两组中位总生存期均未达到(HR 0.980,95%CI 0.686-1.400)。
- ≥3级TEAE发生率:伊布替尼+CIT组85.6%,安慰剂+CIT组75.4%。
- 两组各有13例患者发生导致死亡的TEAE。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 3 SELENE study evaluated ibrutinib + chemoimmunotherapy (CIT; bendamustine and rituximab [BR]; or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL). Adult patients who had received ≥1 prior line of CIT were randomized 1:1 to oral ibrutinib (560 mg) or placebo daily, plus 6 cycles of BR/R-CHOP. The primary end point was investigator-assessed progression-free survival (PFS). Overall, 403 patients were randomized to ibrutinib + CIT (n = 202) or placebo + CIT (n = 201). Most patients received BR (90.3%) and had FL (86.1%). With a median follow-up of 84 months, median PFS was 40.5 months in the ibrutinib + CIT arm and 23.8 months in the placebo + CIT arm (hazard ratio [HR], 0.806; 95% confidence interval [CI], 0.626-1.037; P = .0922). Median overall survival was not reached in either arm (HR, 0.980; 95% CI, 0.686-1.400). Grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 85.6% and 75.4% of patients in the ibrutinib + CIT and placebo + CIT arms, respectively. In each arm, 13 patients had TEAEs leading to death. The addition of ibrutinib to CIT did not significantly improve PFS compared with placebo + CIT. The safety profile was consistent with known profiles of ibrutinib and CIT. This trial was registered at www.clinicaltrials.gov as #NCT01974440.
引用
- Nastoupil LJ, Hess G, Pavlovsky MA, et al. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023. PMID: 37722354. doi:10.1182/bloodadvances.2023010298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。